Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance

作者
Ruoshuang Han,Yijun Jia,Xuefei Li,Chao Zhao,Sha Zhao,Sangtian Liu,Yiwei Liu,Donglai Chen,Qian Zhang,Xiaozhen Liu,Jinpeng Shi,Jiayu Li,Caicun Zhou
出处
期刊:Translational lung cancer research [AME Publishing Company]
卷期号:10 (3): 1277-1291 被引量:26
标识
DOI:10.21037/tlcr-20-1153
摘要

Background: Resistance is almost inevitable and is still a major obstacle in epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Only limited relevant clinical studies evaluated the therapeutic effects by combing metformin and EGFR-TKIs in non-small cell lung cancer (NSCLC) patients. Therefore, we evaluated the efficacy of concurrent use of metformin with EGFR-TKIs, and assessed whether the addition of metformin may improve clinical outcomes and delay the occurrence of EGFR-TKI resistance.Methods: We conducted cell proliferation and apoptosis assay for investigation of metformin in combination with EGFR-TKIs to overcome EGFR-TKI resistance in vitro. Furthermore, we retrospectively reviewed clinicopathological characteristics and therapeutic outcomes of EGFR-mutant advanced NSCLC diabetic patients who received EGFR-TKIs with or without concurrent use of metformin.Results: In vitro experiment, metformin showed synergistic interaction both with gefitinib in PC9R (CI =0.77) and with osimertinib in PC9R/OR (CI =0.77) in proliferation inhibition assay. Metformin can also augment apoptosis effect of these TKI-resistant cells to EGFR-TKIs. In retrospective cohort, a total of 85 patients were identified (cohort A), in which 28 patients had concurrent use of metformin. The objective response rate in metformin use group was significantly higher (85.7% vs. 47.4%, P=0.001). The median progression-free survival (PFS) and overall survival (OS) in metformin use group were significantly longer (21.6 vs. 9.2 months, P=0.000; 48.4 vs. 36.6 months, P=0.049). Further analysis revealed that metformin obviously prolonged the median PFS2 of osimertinib treatment among patients who progressed to prior line EGFR-TKIs due to secondary EGFR T790M mutation (cohort B).Conclusions: Our study suggest that concurrent use of metformin could be beneficial to EGFR-mutant NSCLC patients treated with either first-line EGFR-TKIs or second-line osimertinib.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
矮小的猕猴桃完成签到,获得积分10
1秒前
QinMengYao完成签到 ,获得积分10
1秒前
1秒前
mllll发布了新的文献求助50
2秒前
万能图书馆的应助被小芳芳采纳,获得10
2秒前
green完成签到,获得积分10
2秒前
qq完成签到,获得积分10
3秒前
4秒前
4秒前
SciGPT的应助被丹亦采纳,获得10
5秒前
6秒前
yaoyaoy完成签到,获得积分10
7秒前
夕禾完成签到,获得积分10
7秒前
布丁奶绿lv完成签到,获得积分10
7秒前
green发布了新的文献求助10
8秒前
8秒前
和谐秋荷完成签到,获得积分10
8秒前
9秒前
小安发布了新的文献求助10
9秒前
范范范完成签到 ,获得积分10
9秒前
焦哈哈发布了新的文献求助10
9秒前
9秒前
深情安青的应助被乐观冥幽采纳,获得10
9秒前
9秒前
10秒前
10秒前
10秒前
10秒前
10秒前
窦天蓝完成签到,获得积分10
10秒前
10秒前
完美世界的应助被XH采纳,获得10
10秒前
10秒前
10秒前
10秒前
11秒前
11秒前
11秒前
lan2720完成签到 ,获得积分10
11秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181892
求助须知:如何正确求助?哪些是违规求助? 9571628
关于积分的说明 21818984
捐赠科研通 7778258
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557720
邀请新用户注册赠送积分活动 2479621